Literature DB >> 26206754

Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis.

Levent Ozsari1, Merve Kutahyalioglu1,2, Khaled M Elsayes3, Rafael Andres Vicens3, Kanishka Sircar4, Tarek Jazaerly4, Steven G Waguespack1, Naifa L Busaidy1, Maria E Cabanillas1, Ramona Dadu1, Mimi I Hu1, Rena Vassilopoulou-Sellin1, Camilo Jimenez1, Jeffrey E Lee5, Mouhammed Amir Habra6.   

Abstract

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy that is usually large (>5 cm) at time of diagnosis. Delayed diagnosis significantly worsens survival. We describe adrenal gland morphology prior to ACC diagnosis and discern potential causes of delayed diagnosis. ACC patients seen at The University of Texas MD Anderson Cancer Center between 1998 and 2014 who had cross-sectional body imaging ≥3 months prior to their diagnosis. We conducted a detailed review of clinical and radiological features in these patients prior to ACC diagnosis. Of 439 patients with ACC, 25 had imaging preceding ACC diagnosis (5 with normal adrenal glands and 20 with preexisting masses). On the first available images, the median mass size was 2.8 cm (range 0-9) with median precontrast density of 36 Hounsfield units (range 17-43) and became 9 cm (range 1-18) at the time of ACC diagnosis. The median interval between first available image and ACC diagnosis was 20 months (range 3-89). In the 5 patients whose initial images showed normal adrenal glands, the time between the last normal scan and ACC diagnosis ranged from 5 to 36 months. The most common reason for delayed ACC diagnosis was the presumed benign status of the preexisting mass (n = 13, 65 %). Radiologically suspicious adrenal masses can precede ACC diagnosis and have variable growth patterns. ACC can also develop de novo within a few months in a radiologically documented normal adrenal gland. The presumed benignancy of preexisting masses based on size is the main reason for delayed ACC diagnosis.

Entities:  

Keywords:  Adrenocortical carcinoma; Computed tomography; Delayed diagnosis; Hounsfield units

Mesh:

Year:  2015        PMID: 26206754     DOI: 10.1007/s12020-015-0694-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  25 in total

1.  Pathologic features of prognostic significance in adrenocortical carcinoma.

Authors:  L M Weiss; L J Medeiros; A L Vickery
Journal:  Am J Surg Pathol       Date:  1989-03       Impact factor: 6.394

Review 2.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

3.  Limitations of size as a criterion in the evaluation of adrenal tumors.

Authors:  C C Barnett; D G Varma; A K El-Naggar; A P Dackiw; G A Porter; A S Pearson; A P Kudelka; R F Gagel; D B Evans; J E Lee
Journal:  Surgery       Date:  2000-12       Impact factor: 3.982

4.  Discerning malignancy in adrenocortical tumors: are molecular markers useful?

Authors:  C Wachenfeld; F Beuschlein; O Zwermann; P Mora; M Fassnacht; B Allolio; M Reincke
Journal:  Eur J Endocrinol       Date:  2001-09       Impact factor: 6.664

5.  Management of the clinically inapparent adrenal mass ("incidentaloma").

Authors:  Melvin M Grumbach; Beverly M K Biller; Glenn D Braunstein; Karen K Campbell; J Aidan Carney; Paul A Godley; Emily L Harris; Joseph K T Lee; Yolanda C Oertel; Mitchell C Posner; Janet A Schlechte; H Samuel Wieand
Journal:  Ann Intern Med       Date:  2003-03-04       Impact factor: 25.391

Review 6.  Genetics of the hamartomatous polyposis syndromes: a molecular review.

Authors:  Hui-Min Chen; Jing-Yuan Fang
Journal:  Int J Colorectal Dis       Date:  2009-04-21       Impact factor: 2.571

Review 7.  Precursor lesions of the adrenal gland.

Authors:  F H van Nederveen; R R de Krijger
Journal:  Pathobiology       Date:  2007       Impact factor: 4.342

8.  Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?

Authors:  T J Cawood; P J Hunt; D O'Shea; D Cole; S Soule
Journal:  Eur J Endocrinol       Date:  2009-05-13       Impact factor: 6.664

9.  Morphologic features of 211 adrenal masses at initial contrast-enhanced CT: can we differentiate benign from malignant lesions using imaging features alone?

Authors:  Julie H Song; David J Grand; Michael D Beland; Kevin J Chang; Jason T Machan; William W Mayo-Smith
Journal:  AJR Am J Roentgenol       Date:  2013-12       Impact factor: 3.959

10.  Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center.

Authors:  Montserrat Ayala-Ramirez; Sina Jasim; Lei Feng; Shamim Ejaz; Ferhat Deniz; Naifa Busaidy; Steven G Waguespack; Aung Naing; Kanishka Sircar; Christopher G Wood; Lance Pagliaro; Camilo Jimenez; Rena Vassilopoulou-Sellin; Mouhammed Amir Habra
Journal:  Eur J Endocrinol       Date:  2013-10-23       Impact factor: 6.664

View more
  8 in total

1.  Massive adrenocortical carcinoma presenting as peripheral edema: a case report.

Authors:  David A Goodkin
Journal:  J Med Case Rep       Date:  2022-06-20

2.  Comparison of MRI features in lipid-rich and lipid-poor adrenal adenomas using subjective and quantitative analysis.

Authors:  Wendy Tu; Rosalind Gerson; Jorge Abreu-Gomez; Amar Udare; Rachel Mcphedran; Nicola Schieda
Journal:  Abdom Radiol (NY)       Date:  2021-06-12

3.  Is there a role for epithelial-mesenchymal transition in adrenocortical tumors?

Authors:  Daniel Bulzico; Paulo Antônio Silvestre de Faria; Camila Bravo Maia; Marcela Pessoa de Paula; Davi Coe Torres; Gerson Moura Ferreira; Bruno Ricardo Barreto Pires; Rocio Hassan; Eliana Abdelhay; Mario Vaisman; Leonardo Vieira Neto
Journal:  Endocrine       Date:  2017-09-08       Impact factor: 3.633

4.  Small adrenal incidentaloma becoming an aggressive adrenocortical carcinoma in a patient carrying a germline APC variant.

Authors:  Nadia Gagnon; Pascale Boily; Catherine Alguire; Gilles Corbeil; Irina Bancos; Mathieu Latour; Catherine Beauregard; Katia Caceres; Zaki El Haffaf; Fred Saad; Harold J Olney; Isabelle Bourdeau
Journal:  Endocrine       Date:  2020-02-22       Impact factor: 3.633

5.  Recommendations for the management of adrenal incidentalomas: what is pertinent for radiologists?

Authors:  Anju Sahdev
Journal:  Br J Radiol       Date:  2017-02-09       Impact factor: 3.039

6.  Adrenocortical carcinoma: presentation and outcome of a contemporary patient series.

Authors:  Iiro Kostiainen; Liisa Hakaste; Pekka Kejo; Helka Parviainen; Tiina Laine; Eliisa Löyttyniemi; Mirkka Pennanen; Johanna Arola; Caj Haglund; Ilkka Heiskanen; Camilla Schalin-Jäntti
Journal:  Endocrine       Date:  2019-04-12       Impact factor: 3.925

7.  Radiomics approach based on biphasic CT images well differentiate "early stage" of adrenal metastases from lipid-poor adenomas: A STARD compliant article.

Authors:  Lixiu Cao; Wengui Xu
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

Review 8.  Is Follow-up of Adrenal Incidentalomas Always Mandatory?

Authors:  Giuseppe Reimondo; Alessandra Muller; Elisa Ingargiola; Soraya Puglisi; Massimo Terzolo
Journal:  Endocrinol Metab (Seoul)       Date:  2020-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.